Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1219-1228

  McKibben, Rebeccah A ^a   Margolick, Joseph B ^b   Grinspoon, Steven ^c   Li, Xiuhong ^b   Palella, Frank J ^d   Kingsley, Lawrence A ^e   Witt, Mallory D ^f   George, Richard T ^a   Jacobson, Lisa P ^b   Budoff, Matthew ^f   Tracy, Russell P ^g   Brown, Todd T ^a   Post, Wendy S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

atherosclerosis; human immunodeficiency virus; inflammation; monocyte activation; plaque

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; CELL MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; VIRUS RNA; BIOLOGICAL MARKER; CALCIUM; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CELL LEVEL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; VIRUS IDENTIFICATION; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ANGIOGRAPHY; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; PROCEDURES;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; BIOMARKERS; CALCIUM; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL2; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; PREVALENCE; RECEPTORS, CELL SURFACE; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926646827     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu594     Document Type: Article

References (45)

1. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-8.
2. Palella FJ Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
3. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-12.
4. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116-25.
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocar-dial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
6. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22.
7. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr 2014; 65:160-6.
8. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-53.
9. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014; 160:458-67.
10. van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47:1117-23.
11. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:2045-51.
12. Weaver LK, Hintz-Goldstein KA, Pioli PA, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006; 80:26-35.
13. Joven J, Coll B, Tous M, et al. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattrac-tant protein-1 and carotid atherosclerosis. Clin Chim Acta 2006; 368:114-9.
14. Koenig W, Khuseyinova N, Hoffmann MM, et al. CD14 C(-260)->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002; 40:34-42.
15. Matsushita N, Kashiwagi M, Wait R, et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 2002; 130:156-61.
16. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a muco-sal catastrophe? Nat Immunol 2006; 7:235-9.
17. Gonzalez-Escribano MF, Torres B, Aguilar F, et al. MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis. Hum Immunol 2003; 64:741-4.
18. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 2013; 18:2352-63.
19. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by mono-cyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011; 204:154-63.
20. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-67.
21. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006; 184:342-7.
22. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-36.
23. Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737-46.
24. Longenecker CT, Funderburg NT, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-90.
25. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358:1336-45.
26. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003; 228:826-33.
27. van Werkhoven JM, Schuijf JD, Gaemperli O, et al. Prognostic value of multislice computed tomography and gated single-photon emission computed tomography in patients with suspected coronary artery disease. J Am Coll Cardiol 2009; 53:623-32.
28. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114:1761-91.
29. Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Catheter Cardiovasc Interv 2010; 76:E1-42.
30. Voros S, Rinehart S, Qian Z, et al. Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis. JACC Cardiovasc Imaging 2011; 4:537-48.
31. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-8.
32. Hacioglu Y, Gupta M, Choi TY, et al. Use of cardiac CT angiography imaging in an epidemiology study-the methodology of the Multicenter AIDS Cohort Study cardiovascular disease substudy. Anadolu Kardiyol Derg 2013; 13:207-14.
33. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15:827-32.
34. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51:5-40.
35. Pagali SR, Madaj P, Gupta M, et al. Interobserver variations of plaque severity score and segment stenosis score in coronary arteries using 64 slice multidetector computed tomography: a substudy of the ACCURACY trial. J Cardiovasc Comput Tomogr 2010; 4:312-8.
36. Schafer JL. Analysis of incomplete multivariate data. London: Chapman & Hall, 1997.
37. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediat-ed chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 1998; 18:1983-91.
38. Shaked I, Hanna DB, Gleissner C, et al. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol 2014; 34:1085-92.
39. Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-77.
40. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110:2204-9.
41. Floris-Moore M, Fayad ZA, Berman JW, et al. Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS 2009; 23:941-9.
42. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005; 112:1113-20.
43. Schnabel RB, Baumert J, Barbalic M, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2010; 115:5289-99.
44. Ahmadi N, Nabavi V, Hajsadeghi F, et al. Mortality incidence of patients with non-obstructive coronary artery disease diagnosed by computed tomography angiography. Am J Cardiol 2011; 107:10-6.
45. Knudsen A, Moller HJ, Katzenstein TL, et al. Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis 2013; 13:230.